Evrópusambandið - íslenska - EMA (European Medicines Agency)

teva b.v. - salmeterol xinafoate, flútikasón nef - astma - lyf til veikindi öndunarvegi sjúkdómum, - bropair spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β₂ agonists.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

mundipharma a/s - fluticasonum própíónat; formoterolum fúmarat - innúðalyf, dreifa - 125 míkróg/5 míkróg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

mundipharma a/s - fluticasonum própíónat; formoterolum fúmarat - innúðalyf, dreifa - 250 míkróg/10 míkróg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

mundipharma a/s - fluticasonum própíónat; formoterolum fúmarat - innúðalyf, dreifa - 50 míkróg/5 míkróg